GT Biopharma, Inc., a clinical-stage biopharmaceutical company based in Brisbane, California, specializes in developing immuno-oncology therapies using its proprietary TriKE NK cell engager platform. Their key product, GTB-3550, targets cancer through a fusion protein that enhances the cancer-killing abilities of a patient's natural killer cells, with ongoing clinical trials and potential applications in infectious disease treatment.
GT Biopharma (GTBP) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, GT Biopharma's actual EPS was -$1.64, beating the estimate of -$2.75 per share, resulting in a 40.45% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
